-
Life Science Tools & Diagnostics stocks: Q2 earnings preview
-
Citi Downgrades Charles River Labs (CRL) to Neutral, 'limited catalysts in 2H23 for the core business'
-
UPDATE: Citi Upgrades Charles River Labs (CRL) to Buy, 'Sell-Off Creates Compelling Entry Point'
-
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
-
Charles River Labs (CRL) PT Raised to $104 at Citi
-
Charles River Labs (CRL) PT Raised to $91 at Citi
-
Notable Analyst Rating Changes 7/10: (COST) (RIO) (AGI) Upgraded; (CRL) (IAG) (RAX) Downgraded
-
Pre-Open Stock Movers 02/11: (BLDP) (CHS) (LGF) Higher; (PIR) (DCTH) (WBAI) Lower (more...)
-
Citi Starts Charles River Labs (CRL) at Neutral
-
StreetInsider.com Pre-Open Movers 4/03: (CALL) (ZNGA) (OMPI) Higher; (GPN) (CAG) (VOD) Lower (more...)
-
Citi Downgrades Charles River Labs (CRL) to Sell
-
Viking Global Shows New Stakes In Apple (AAPL), Citi (C); Sells Out of JPMorgan (JPM), Morgan Stanley (MS)
-
Citi Starts Charles River Labs (CRL) at Hold
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
David Moenning's Daily State of the Markets: 5/6
-
David Moenning's Daily State of the Markets: 4/24
-
David Moenning's Daily State of the Markets: 4/20
-
David Moenning's Daily State of the Markets: 3/13
-
David Moenning's Daily State of the Markets: 2/12

